Key facts
- Beyond Barriers Therapeutics’s last known valuation is $12.5M (Jul 2025).
- It has raised $2.5M; the latest was Seed Round ($2.5M) in Jul 2025.
- Notable investors include GrowthX Capital.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Beyond Barriers Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Beyond Barriers Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Beyond Barriers Therapeutics
Developer of an intranasally delivered therapeutic intended to treat inflammation and cell death following traumatic brain injury (TBI). The company's intranasal device can be administered immediately after impact to the head to directly slow or prevent the harmful process from further damaging neural tissue, enabling doctors to improve active therapy.
- Sector
- Healthcare
- HQ
- Chicago, IL, United States
- Founded
- 2015
- Employees
- 5
- Ownership
- Privately Held (backing)
Beyond Barriers Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Beyond Barriers Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Beyond Barriers Therapeutics in its N-PORT filings yet. We sweep new filings monthly.